The purpose of this study was to investigate the effect of supplementary vitamin D
therapy in addition to amitriptyline on the frequency of migraine attacks in
pediatric migraine patients. Fifty-three children 8-16 years of age and diagnosed
with migraine following the International Headache Society 2005 definition, which
includes childhood criteria, were enrolled. Patients were classified into four groups
on the basis of their 25-hydroxyvitamin D [25(OH)D] levels. Group 1 had normal
25(OH)D levels and received amitriptyline therapy alone; group 2 had normal 25(OH)D
levels and received vitamin D supplementation (400 IU/day) plus amitriptyline; group
3 had mildly deficient 25(OH)D levels and received amitriptyline plus vitamin D (800
IU/day); and group 4 had severely deficient 25(OH)D levels and was given
amitriptyline plus vitamin D (5000 IU/day). All groups were monitored for 6 months,
and the number of migraine attacks before and during treatment was determined.
Calcium, phosphorus alkaline phosphatase, parathormone, and 25(OH)D levels were also
determined before and during treatment. Results were compared between the groups.
Data obtained from the groups were analyzed using one-way analysis of variance. The
number of pretreatment attacks in groups 1 to 4 was 7±0.12, 6.8±0.2, 7.3±0.4, and
7.2±0.3 for 6 months, respectively (all P>0.05). The number of attacks during
treatment was 3±0.25, 1.76±0.37 (P<0.05), 2.14±0.29 (P<0.05), and 1.15±0.15
(P<0.05), respectively. No statistically significant differences in calcium,
phosphorus, alkaline phosphatase, or parathormone levels were observed (P>0.05).
Vitamin D given in addition to anti-migraine treatment reduced the number of migraine
attacks.